Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LGND $SAGE SAGE-547 SRSE Data Highlight The Advantage Of Ligand's Technology, Says Roth Capital http://www.smarteranalyst.com/2014/11/11/sage-547-srse-data-highlight-the-advantage-of-ligands-technology-says-roth-capital/
$IMUC Roth Capital Maintains Buy On ImmunoCellular Following 3Q:14 Update http://www.smarteranalyst.com/2014/11/11/roth-capital-maintains-buy-on-immunocellular-following-3q14-update/
$CLDX Roth Capital Reiterates Buy On Celldex Following Initiation Of Phase Ib Combination Study http://www.smarteranalyst.com/2014/11/11/roth-capital-reiterates-buy-on-celldex-following-initiation-of-phase-ib-combination-study/
$KERX Maxim Group Comments On Keryx Following Negative Commentary http://www.smarteranalyst.com/2014/11/11/maxim-group-comments-on-keryx-following-negative-commentary/
$RPRX Brean Capital Reiterates Buy On Repros As There Are No Surprises In 3Q14 Report http://www.smarteranalyst.com/2014/11/11/brean-capital-reiterates-buy-on-repros-as-there-are-no-surprises-in-3q14-report/
$RMTI Brean Capital Comments On Rockwell Medical Following FDA Panel Vote http://www.smarteranalyst.com/2014/11/11/brean-capital-comments-on-rockwell-medical-following-fda-panel-vote/
$MACK Brean Capital Remains Positive On Merrimack Despite NDA Submission Delay http://www.smarteranalyst.com/2014/11/11/brean-capital-remains-positive-on-merrimack-despite-nda-submission-delay/
$INO Brean Capital Reiterates Buy On Inovio As More Key Clinical Results Coming In 2015 http://www.smarteranalyst.com/2014/11/11/brean-capital-reiterates-buy-on-inovio-as-more-key-clinical-results-coming-in-2015/
$INO Brean Capital Reiterates Buy On Inovio As More Key Clinical Results Coming In 2015 http://www.smarteranalyst.com/2014/11/11/brean-capital-reiterates-buy-on-inovio-as-more-key-clinical-results-coming-in-2015/
H.C. Wainwright Reiterates Buy On OvaScience, Increases PT To $40 http://www.smarteranalyst.com/2014/11/11/h-c-wainwright-reiterates-buy-on-ovascience-increases-pt-to-40/
$TWTR Cantor Comments On Twitter Ahead Of Its First Analyst Day http://www.smarteranalyst.com/2014/11/11/cantor-comments-on-twitter-ahead-of-its-first-analyst-day/
$NRF MLV Comments On Northstar Realty Finance Following 3Q14 Results http://www.smarteranalyst.com/2014/11/11/mlv-comments-on-northstar-realty-finance-following-3q14-results/
$APP Roth Capital Maintains Buy On American Apparel Following Earnings http://www.smarteranalyst.com/2014/11/11/roth-capital-maintains-buy-on-american-apparel-following-earnings/
$HYGS Roth Capital Cuts Hydrogenics Price Target To Reflect A More Conservative 2015 Forecast http://www.smarteranalyst.com/2014/11/11/roth-capital-cuts-hydrogenics-price-target-to-reflect-a-more-conservative-2015-forecast/
$NPSP Brean Capital Reiterates Buy On NPS Pharmaceuticals Following 3Q14 Results http://www.smarteranalyst.com/2014/11/11/brean-capital-reiterates-buy-on-nps-pharmaceuticals-following-3q14-results/
$CPRX H.C. Wainwright Maintains Buy On Catalyst Pharmaceutical Following Presentation At AANEM http://www.smarteranalyst.com/2014/11/11/h-c-wainwright-maintains-buy-on-catalyst-pharmaceutical-following-presentation-at-aanem/
$PGNX Brean Capital Reiterates Buy On Progenics Following 3Q14 Results; Keeps $11 PT http://www.smarteranalyst.com/2014/11/10/brean-capital-reiterates-buy-on-progenics-following-3q14-results-keeps-11-pt/
$CNAT MLV Maintains Buy On Conatus Pharmaceuticals Following Phase 1 Data In Hepatic Impairment http://www.smarteranalyst.com/2014/11/10/mlv-maintains-buy-on-conatus-pharmaceuticals-following-phase-1-data-in-hepatic-impairment/
$MHR MLV Cuts Magnum Hunter Resources Price Target On Widening Gas Price Differentials http://www.smarteranalyst.com/2014/11/10/mlv-cuts-magnum-hunter-resources-price-target-on-widening-gas-price-differentials/
MLV Maintains Buy On Prospect Capital But Reduced PT To $11 http://www.smarteranalyst.com/2014/11/10/mlv-maintains-buy-on-prospect-capital-but-reduced-pt-to-11/
$ANF Oppenheimer Moves To The Sidelines On Abercrombie; Cuts PT To $30 http://www.smarteranalyst.com/2014/11/10/oppenheimer-moves-to-the-sidelines-on-abercrombie-cuts-pt-to-30/
$OXGN MLV Maintains Buy On Oxigene Following Presentation Of Phase 2 Data In Recurrent Ovarian Cancer http://www.smarteranalyst.com/2014/11/10/mlv-maintains-buy-on-oxigene-following-presentation-of-phase-2-data-in-recurrent-ovarian-cancer/
$OXGN MLV Maintains Buy On Oxigene Following Presentation Of Phase 2 Data In Recurrent Ovarian Cancer http://www.smarteranalyst.com/2014/11/10/mlv-maintains-buy-on-oxigene-following-presentation-of-phase-2-data-in-recurrent-ovarian-cancer/
$CDTI Roth Capital Maintains Buy On Clean Diesel Shares, Sees 41% Upside http://www.smarteranalyst.com/2014/11/10/roth-capital-maintains-buy-on-clean-diesel-shares-sees-41-upside/
Roth Capital Maintains Buy On Clean Diesel Shares, Sees 41% Upside http://www.smarteranalyst.com/2014/11/10/roth-capital-maintains-buy-on-clean-diesel-shares-sees-41-upside/
$SLXP Cantor Cuts Salix Pharmaceuticals Price Target On Inventory Disclosure http://stks.co/j1I04
$SLXP Cantor Cuts Salix Pharmaceuticals Price Target On Inventory Disclosure http://stks.co/j1I04
$CYTX Maxim Group Reaffirms Buy On Cytori Therapeutics Following 3Q:14 Update http://www.smarteranalyst.com/2014/11/10/maxim-group-reaffirms-buy-on-cytori-therapeutics-following-3q14-update/
$CYTX Maxim Group Reaffirms Buy On Cytori Therapeutics Following 3Q:14 Update http://www.smarteranalyst.com/2014/11/10/maxim-group-reaffirms-buy-on-cytori-therapeutics-following-3q14-update/
$AEZS Aeterna Zentaris: The Damage Is Done, Don't Sell Now, Says Maxim http://www.smarteranalyst.com/2014/11/10/aeterna-zentaris-the-damage-is-done-dont-sell-now-says-maxim/
$AEZS Aeterna Zentaris: The Damage Is Done, Don't Sell Now, Says Maxim http://www.smarteranalyst.com/2014/11/10/aeterna-zentaris-the-damage-is-done-dont-sell-now-says-maxim/
$INO Maxim Group Maintains Buy On Inovio Pharmaceuticals Following 3Q14 Update http://www.smarteranalyst.com/2014/11/10/maxim-group-maintains-buy-on-inovio-pharmaceuticals-following-3q14-update/
$PPHM Roth Capital Maintains Buy On Peregrine Following Presentation Of Bavituximab Phase II Study http://www.smarteranalyst.com/2014/11/10/roth-capital-maintains-buy-on-peregrine-following-presentation-of-bavituximab-phase-ii-study/
$RPRX Brean Capital Reiterates Buy On Repros Therapeutics Following FDA Meeting http://www.smarteranalyst.com/2014/11/10/brean-capital-reiterates-buy-on-repros-therapeutics-following-fda-meeting/
$RPRX Brean Capital Reiterates Buy On Repros Therapeutics Following FDA Meeting http://www.smarteranalyst.com/2014/11/10/brean-capital-reiterates-buy-on-repros-therapeutics-following-fda-meeting/
$ACRX Roth Capital Remains Neutral On Acelrx As CEO Richard King Steps Down http://www.smarteranalyst.com/2014/11/10/roth-capital-remains-neutral-on-acelrx-as-ceo-richard-king-steps-down/
$TKMR Maxim Maintains Buy On Tekmira Following 3Q14 Results http://www.smarteranalyst.com/2014/11/10/maxim-maintains-buy-on-tekmira-following-3q14-results/
$MNTA Maxim Group Reiterates Buy On Momenta Pharmaceuticals Following 3Q14 Results http://www.smarteranalyst.com/2014/11/10/maxim-group-reiterates-buy-on-momenta-pharmaceuticals-following-3q14-results/
$URRE Roth Capital Cuts Uranium Resources Price Target, Still Sees 80% Upside http://www.smarteranalyst.com/2014/11/07/roth-capital-cuts-uranium-resources-price-target-but-still-sees-80-upside/
$URRE Roth Capital Cuts Uranium Resources Price Target, Still Sees 80% Upside http://www.smarteranalyst.com/2014/11/07/roth-capital-cuts-uranium-resources-price-target-but-still-sees-80-upside/